
|Videos|January 19, 2023
Efficacy and Safety of JAK inhibitors for AD
Author(s)Brett King, MD, PhD, Alexandra K. Golant, MD
Experts in atopic disease management review the efficacy and safety data of the JAK inhibitor class, highlighting the importance of time to treatment response and itch reduction.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Oral C5aR Inhibitor INF904 Shows Early Efficacy in HS and CSU Phase 2a Trials
2
Long-Term Strategies and Response Markers in Vitiligo Management
3
Derm Dispatch at SDPA Fall 2025: The Social Media Skin Care Crisis
4
Balancing Social Media's Necessity and AI's Coming Transformation
5






















